{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:53:00Z","timestamp":1769104380953,"version":"3.49.0"},"reference-count":195,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007388","name":"Compagnia di San Paolo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.hfc.2021.01.002","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T10:26:38Z","timestamp":1612952798000},"page":"223-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Biomarkers in Heart Failure"],"prefix":"10.1016","volume":"17","author":[{"given":"Andrea","family":"Salzano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"D\u2019Assante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Zubair","family":"Israr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Eltayeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Bernieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarosaria","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Rega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigida","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Bossone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain B.","family":"Squire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto M.","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.hfc.2021.01.002_bib2","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation\/American heart association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2012.10.002","article-title":"Heart failure","volume":"1","author":"Braunwald","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10.1016\/j.hfc.2021.01.002_bib5","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American heart association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1253\/circj.CJ-08-1157","article-title":"Cardiovascular diagnostic biomarkers: the past, present and future","volume":"73","author":"Suzuki","year":"2009","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.hfc.2017.08.010","article-title":"Proteomic biomarkers of heart failure","volume":"14","author":"Israr","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib8","doi-asserted-by":"crossref","first-page":"ix","DOI":"10.1016\/j.hfc.2017.08.012","article-title":"Biomarkers of heart failure: past, present, and future","volume":"14","author":"Suzuki","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jchf.2017.01.008","article-title":"Limited added value of circulating inflammatory biomarkers in chronic heart failure","volume":"5","author":"Nymo","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.hfc.2018.12.008","article-title":"Biomarkers and imaging: complementary or subtractive?","volume":"15","author":"Salzano","year":"2019","journal-title":"Heart Fail Clin"},{"issue":"22","key":"10.1016\/j.hfc.2021.01.002_bib11","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American heart association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"20","key":"10.1016\/j.hfc.2021.01.002_bib13","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1586\/14737159.3.5.525","article-title":"Biomarkers: current perspectives and future prospects","volume":"3","author":"Naylor","year":"2003","journal-title":"Expert Rev Mol Diagn"},{"issue":"9","key":"10.1016\/j.hfc.2021.01.002_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002528","article-title":"Established and emerging roles of biomarkers in heart failure clinical trials","volume":"9","author":"Ibrahim","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10.1016\/j.hfc.2021.01.002_bib16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jchf.2018.02.008","article-title":"Will biomarkers succeed as a surrogate endpoint in heart failure trials?","volume":"6","author":"Januzzi","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/HCO.0000000000000254","article-title":"Current and novel biomarkers in heart failure: bench to bedside","volume":"31","author":"Ghashghaei","year":"2016","journal-title":"Curr Opin Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib18","first-page":"416","article-title":"Editor's choice-biomarkers of acute cardiovascular and pulmonary diseases","volume":"5","author":"Suzuki","year":"2016","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1878-5085-4-7","article-title":"Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine","volume":"4","author":"Drucker","year":"2013","journal-title":"EPMA J"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1602\/neurorx.1.2.182","article-title":"Biomarkers: potential uses and limitations","volume":"1","author":"Mayeux","year":"2004","journal-title":"NeuroRx"},{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.106.683110","article-title":"Benchmarks for the assessment of novel cardiovascular biomarkers","volume":"115","author":"Morrow","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310","author":"Ledwidge","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.hfc.2021.01.002_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ejhf.286","article-title":"Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study","volume":"17","author":"Ledwidge","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijcard.2013.08.089","article-title":"NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: results of the SCReening evaluation of the evolution of new heart failure study (SCREEN-HF)","volume":"169","author":"McGrady","year":"2013","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ejhf.1381","article-title":"Prediction of incident heart failure by serum amino-terminal pro-B-type natriuretic peptide level in a community-based cohort","volume":"21","author":"Campbell","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1388-9842(03)00108-9","article-title":"Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate","volume":"5","author":"Loke","year":"2003","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.hfc.2021.01.002_bib27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","article-title":"Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis","volume":"4","author":"Natriuretic Peptides Studies Collaboration","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ejhf.1391","article-title":"Measurement of circulating natriuretic peptides to identify community-based patients at risk of incident heart failure - should we?","volume":"21","author":"Squire","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jchf.2020.01.005","article-title":"Prediction of incident heart failure: is it time for routine screening?","volume":"8","author":"Gaggin","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib30","article-title":"Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers","author":"Clerico","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"22","key":"10.1016\/j.hfc.2021.01.002_bib31","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1001\/jama.2010.1708","article-title":"Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults","volume":"304","author":"deFilippi","year":"2010","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jchf.2019.12.008","article-title":"High-sensitivity cardiac troponin I levels and prediction of heart failure: results from the BiomarCaRE consortium","volume":"8","author":"Yan","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/CIRCHEARTFAILURE.114.001185","article-title":"Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort","volume":"7","author":"Brouwers","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"21","key":"10.1016\/j.hfc.2021.01.002_bib34","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/heartjnl-2014-305968","article-title":"ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality","volume":"100","author":"Hughes","year":"2014","journal-title":"Heart"},{"issue":"13","key":"10.1016\/j.hfc.2021.01.002_bib35","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1161\/CIRCULATIONAHA.112.129437","article-title":"Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study","volume":"126","author":"Wang","year":"2012","journal-title":"Circulation"},{"issue":"9280","key":"10.1016\/j.hfc.2021.01.002_bib36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0140-6736(01)05620-3","article-title":"Prevalence of left-ventricular systolic dysfunction and heart failure in the echocardiographic heart of England screening study: a population based study","volume":"358","author":"Davies","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1388-9842(03)00154-5","article-title":"Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography","volume":"5","author":"Ng","year":"2003","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib38","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacc.2003.10.043","article-title":"Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction","volume":"43","author":"Heidenreich","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2021.01.002_bib39","article-title":"Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects","author":"Gori","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.hfc.2021.01.002_bib40","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2004.12.058","article-title":"Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides","volume":"45","author":"Ng","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2005.09.020","article-title":"Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure","volume":"152","author":"Ng","year":"2006","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib42","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/ehf2.12496","article-title":"Heart failure prevalence in the general population: SOBOTA-HF study rationale and design","volume":"6","author":"Lainscak","year":"2019","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/2047487319893035","article-title":"Update on cardiovascular prevention in clinical practice: a position paper of the European association of preventive cardiology of the european society of cardiology","volume":"27","author":"Piepoli","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hfc.2017.08.002","article-title":"Natriuretic peptides in heart failure: atrial and B-type natriuretic peptides","volume":"14","author":"Maisel","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.hfc.2017.08.004","article-title":"N-terminal B-type natriuretic peptide in heart failure","volume":"14","author":"Richards","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart failure association of the European society of cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"10.1016\/j.hfc.2021.01.002_bib47","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.2174\/0929867323666161029223512","article-title":"A\u00a0focused review of gender differences in antithrombotic therapy","volume":"24","author":"Salzano","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.hfc.2021.01.002_bib48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.phrs.2016.10.018","article-title":"Gender-related differences in pulmonary arterial hypertension targeted drugs administration","volume":"114","author":"Marra","year":"2016","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib49","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ejhf.1771","article-title":"Sex-related differences in contemporary biomarkers for heart failure: a review","volume":"22","author":"Suthahar","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib50","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4081\/monaldi.2018.988","article-title":"The impact of gender in cardiovascular medicine: Lessons from the gender\/sex-issue in heart failure","volume":"88","author":"Marra","year":"2018","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.hfc.2021.01.002_bib51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2019.04.023","article-title":"N-terminal pro-B-type natriuretic peptide in chronic heart failure: the impact of sex across the ejection fraction spectrum","volume":"287","author":"Fax\u00e9n","year":"2019","journal-title":"Int J Cardiol"},{"issue":"40","key":"10.1016\/j.hfc.2021.01.002_bib52","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure Association (HFA) of the European society of cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.01.002_bib53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2018.12.069","article-title":"Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases","volume":"280","author":"Kasahara","year":"2019","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2021.01.002_bib54","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-Type natriuretic peptide during treatment with Sacubitril\/Valsartan: the PARADIGM-HF trial","volume":"73","author":"Myhre","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib55","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERP-19-0050","article-title":"Normal reference intervals for cardiac dimensions and function for use in echocardiographic practice: a guideline from the British Society of Echocardiography","volume":"7","author":"Harkness","year":"2020","journal-title":"Echo Res Pract"},{"issue":"12","key":"10.1016\/j.hfc.2021.01.002_bib56","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/2047487318766580","article-title":"N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure","volume":"25","author":"Arzilli","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hfc.2021.01.002_bib58","article-title":"The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review","author":"Rabkin","year":"2020","journal-title":"Heart Fail Rev"},{"issue":"18","key":"10.1016\/j.hfc.2021.01.002_bib59","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.hfc.2021.01.002_bib60","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jacc.2010.06.016","article-title":"Troponin elevation in heart failure prevalence, mechanisms, and clinical implications","volume":"56","author":"Kociol","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.hfc.2021.01.002_bib61","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/eurjhf\/hfr047","article-title":"Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure","volume":"13","author":"Pascual-Figal","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.hfc.2021.01.002_bib62","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/ejhf.341","article-title":"Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study","volume":"17","author":"Felker","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.hfc.2021.01.002_bib63","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/eurjhf\/hfs110","article-title":"Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study","volume":"14","author":"Felker","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10.1016\/j.hfc.2021.01.002_bib64","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa0706824","article-title":"Cardiac troponin and outcome in acute heart failure","volume":"358","author":"Peacock","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.hfc.2021.01.002_bib65","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehs191","article-title":"Troponin elevation in patients with heart failure: on behalf of the third universal definition of myocardial infarction global task force: heart failure section","volume":"33","author":"Januzzi","year":"2012","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.hfc.2021.01.002_bib66","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/01.CIR.0000084543.79097.34","article-title":"Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure","volume":"108","author":"Horwich","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2009.10.022","article-title":"Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure","volume":"159","author":"Tsutamoto","year":"2010","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.hfc.2021.01.002_bib68","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCULATIONAHA.106.655076","article-title":"Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure","volume":"116","author":"Latini","year":"2007","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.hfc.2021.01.002_bib69","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week","volume":"74","author":"Aimo","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.hfc.2017.08.005","article-title":"Soluble ST2 in heart failure","volume":"14","author":"McCarthy","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"7","key":"10.1016\/j.hfc.2021.01.002_bib71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacc.2007.05.014","article-title":"Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study","volume":"50","author":"Januzzi","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib72","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/ehf2.12673","article-title":"Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients","volume":"7","author":"Crnko","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1701","article-title":"Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T","author":"Aimo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2019.11.002","article-title":"Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure","volume":"304","author":"Savvoulidis","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2021.01.002_bib75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijcard.2019.05.046","article-title":"A\u00a0bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score","volume":"293","author":"Lup\u00f3n","year":"2019","journal-title":"Int J Cardiol"},{"issue":"19","key":"10.1016\/j.hfc.2021.01.002_bib76","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2018.08.2165","article-title":"sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T","volume":"72","author":"Emdin","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib77","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223","article-title":"High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure","volume":"4","author":"Ky","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"18","key":"10.1016\/j.hfc.2021.01.002_bib78","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jacc.2008.07.042","article-title":"Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure","volume":"52","author":"Rehman","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib79","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0092-8674(94)90498-7","article-title":"Galectins: a family of animal beta-galactoside-binding lectins","volume":"76","author":"Barondes","year":"1994","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib80","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hfc.2017.08.009","article-title":"Galectin-3 in heart failure: an update of the last 3 years","volume":"14","author":"Gehlken","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib81","article-title":"Circulating Galectin-3 Is associated with cardiometabolic disease in the community","volume":"5","author":"Nayor","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib82","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/eurjhf\/hfq091","article-title":"Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure","volume":"12","author":"Shah","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib83","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib84","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure","volume":"48","author":"van Kimmenade","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib85","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.hfc.2021.01.002_bib86","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/eurheartj\/ehi389","article-title":"The importance of the gastrointestinal system in the pathogenesis of heart failure","volume":"26","author":"Krack","year":"2005","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib87","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hfc.2019.08.001","article-title":"The gut axis involvement in heart failure: focus on trimethylamine N-oxide","volume":"16","author":"Salzano","year":"2020","journal-title":"Heart Fail Clin"},{"issue":"12","key":"10.1016\/j.hfc.2021.01.002_bib88","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2015.09.017","article-title":"Intersections between microbiome and heart failure: revisiting the gut hypothesis","volume":"21","author":"Nagatomo","year":"2015","journal-title":"J\u00a0Card Fail"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib89","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.hfc.2021.01.002_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/2047487319831372","article-title":"Impact of acute choline loading on circulating trimethylamine N-oxide levels","author":"Cassambai","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2021.01.002_bib91","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/heartjnl-2015-308826","article-title":"Trimethylamine N-oxide and prognosis in acute heart failure","volume":"102","author":"Suzuki","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.hfc.2021.01.002_bib92","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ahj.2021.01.006","article-title":"Association of gut-related metabolites with outcome in acute heart failure","volume":"234","author":"Israr","year":"2021","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib93","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/joim.12328","article-title":"Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure","volume":"277","author":"Troseid","year":"2015","journal-title":"J\u00a0Intern Med"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib94","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cardfail.2014.11.006","article-title":"Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure","volume":"21","author":"Tang","year":"2015","journal-title":"J\u00a0Card Fail"},{"issue":"25","key":"10.1016\/j.hfc.2021.01.002_bib95","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1016\/j.jacc.2017.10.064","article-title":"Trimethylamine-N-oxide and heart failure with reduced versus preserved ejection fraction","volume":"70","author":"Schuett","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.hfc.2021.01.002_bib96","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2014.02.617","article-title":"Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis","volume":"64","author":"Tang","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2021.01.002_bib97","article-title":"Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF)","author":"Suzuki","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib98","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1253\/circj.CJ-18-0468","article-title":"Gut microbiome and plasma microbiome-related metabolites in patients with decompensated and compensated heart failure","volume":"83","author":"Hayashi","year":"2018","journal-title":"Circ J"},{"issue":"10","key":"10.1016\/j.hfc.2021.01.002_bib99","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/ejhf.1550","article-title":"Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis","volume":"21","author":"Yazaki","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.12777","article-title":"Ethnic differences in association of outcomes with trimethylamine N-oxide in acute heart failure patients","author":"Yazaki","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib101","article-title":"Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study","author":"Salzano","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/CIRCHEARTFAILURE.108.821892","article-title":"Heart failure as a multiple hormonal deficiency syndrome","volume":"2","author":"Sacc\u00e0","year":"2009","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib103","doi-asserted-by":"crossref","first-page":"FSO311","DOI":"10.4155\/fsoa-2018-0041","article-title":"Multiple hormone deficiency syndrome: a novel topic in chronic heart failure","volume":"4","author":"Salzano","year":"2018","journal-title":"Future Sci OA"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib104","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.hfc.2019.08.012","article-title":"Anabolic deficiencies in heart failure: ready for prime time?","volume":"16","author":"Napoli","year":"2020","journal-title":"Heart Fail Clin"},{"issue":"17","key":"10.1016\/j.hfc.2021.01.002_bib105","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.106.649426","article-title":"Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival","volume":"114","author":"Jankowska","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2021.01.002_bib106","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijcard.2016.02.017","article-title":"Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure","volume":"209","author":"Marra","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2021.01.002_bib107","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijcard.2015.02.055","article-title":"Multiple hormone deficiencies in chronic heart failure","volume":"184","author":"Arcopinto","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2021.01.002_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2016.09.085","article-title":"Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction","volume":"225","author":"Salzano","year":"2016","journal-title":"Int J Cardiol"},{"issue":"18","key":"10.1016\/j.hfc.2021.01.002_bib109","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/jama.2009.639","article-title":"Circulating estradiol and mortality in men with systolic chronic heart failure","volume":"301","author":"Jankowska","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib110","doi-asserted-by":"crossref","first-page":"e0170058","DOI":"10.1371\/journal.pone.0170058","article-title":"Growth hormone deficiency is associated with worse cardiac function, physical performance, and outcome in chronic heart failure: insights from the T.O.S.CA. GHD Study","volume":"12","author":"Arcopinto","year":"2017","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.hfc.2021.01.002_bib111","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1053\/euhj.1999.2043","article-title":"Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure","volume":"21","author":"Suskin","year":"2000","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib112","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacc.2005.02.093","article-title":"Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure","volume":"46","author":"Doehner","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib113","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/1871530311313010010","article-title":"The GH\/IGF-1 axis in chronic heart failure","volume":"13","author":"Arcopinto","year":"2013","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib114","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ijcard.2012.09.215","article-title":"Cardiovascular abnormalities in Klinefelter syndrome","volume":"168","author":"Pasquali","year":"2013","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib115","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1210\/jc.2014-1805","article-title":"Cardiovascular abnormalities and impaired exercise performance in adolescents with congenital adrenal hyperplasia","volume":"100","author":"Marra","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib116","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12020-018-1584-6","article-title":"Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectives","volume":"61","author":"Salzano","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-15-0833","article-title":"Effects of L-thyroxine treatment on early markers of atherosclerotic disease in children with subclinical hypothyroidism","volume":"175","author":"Cerbone","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib118","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/HCO.0000000000000166","article-title":"Hormone replacement therapy in heart failure","volume":"30","author":"Arcopinto","year":"2015","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib119","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.hfc.2018.05.002","article-title":"Growth hormone therapy in heart failure","volume":"14","author":"Salzano","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.hfc.2019.02.007","article-title":"Hormonal replacement therapy in heart failure: focus on growth hormone and testosterone","volume":"15","author":"Salzano","year":"2019","journal-title":"Heart Fail Clin"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib121","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jchf.2013.04.003","article-title":"Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study","volume":"1","author":"Cittadini","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib122","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/ehf2.12520","article-title":"Combined effects of growth hormone and testosterone replacement treatment in heart failure","volume":"6","author":"Salzano","year":"2019","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib123","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11739-018-1844-8","article-title":"Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry","volume":"13","author":"Bossone","year":"2018","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.hfc.2021.01.002_bib124","article-title":"Multiple Hormonal and Metabolic Deficiency Syndrome predicts outcome in heart failure","author":"Cittadini","year":"2021","journal-title":"The T.O.S.CA. Registry. Eur J Prev Cardiol"},{"issue":"23","key":"10.1016\/j.hfc.2021.01.002_bib125","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000455","article-title":"Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American heart association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib126","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: a position paper from the heart failure association of the European society of cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"10.1016\/j.hfc.2021.01.002_bib127","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jama.2017.12131","article-title":"Cancer DNA in the circulation: the liquid biopsy","volume":"318","author":"Husain","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib128","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/ATVBAHA.117.310597","article-title":"MiR-146a regulates neutrophil extracellular trap formation that predicts adverse cardiovascular events in patients with atrial fibrillation","volume":"38","author":"Arroyo","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.recesp.2018.02.020","article-title":"Cell-free DNA and microvascular damage in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"72","author":"Sanchis","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjms.2018.04.007","article-title":"Correlations of circulating cell-free DNA with clinical manifestations in acute myocardial infarction","volume":"356","author":"Xie","year":"2018","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib131","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.atherosclerosis.2013.12.022","article-title":"Circulating cell-free DNA is associated with cardiometabolic risk factors: the Health 2000 Survey","volume":"233","author":"Jylhava","year":"2014","journal-title":"Atherosclerosis"},{"issue":"241","key":"10.1016\/j.hfc.2021.01.002_bib132","doi-asserted-by":"crossref","first-page":"241ra77","DOI":"10.1126\/scitranslmed.3007803","article-title":"Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection","volume":"6","author":"De Vlaminck","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hfc.2021.01.002_bib133","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.cca.2019.06.004","article-title":"Donor-specific circulating cell free DNA as a noninvasive biomarker of graft injury in heart transplantation","volume":"495","author":"Macher","year":"2019","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.hfc.2021.01.002_bib134","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.15339","article-title":"Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study","author":"Khush","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hfc.2021.01.002_bib135","article-title":"Circulating cell-free DNA levels are associated with adverse outcomes in heart failure: testing liquid biopsy in heart failure","author":"Salzano","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hfc.2017.08.001","article-title":"Proenkephalin in heart failure","volume":"14","author":"Siong Chan","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib137","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2016.01.042","article-title":"Prognostic usefulness of proenkephalin in stable ambulatory patients with heart failure","volume":"117","author":"Arbit","year":"2016","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib138","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cardfail.2016.09.007","article-title":"Clinical correlates and prognostic value of proenkephalin in acute and chronic heart failure","volume":"23","author":"Matsue","year":"2017","journal-title":"J\u00a0Card Fail"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib139","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jacc.2016.10.038","article-title":"Proenkephalin, renal dysfunction, and prognosis in patients with acute heart failure: a GREAT network study","volume":"69","author":"Ng","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib140","doi-asserted-by":"crossref","first-page":"e005544","DOI":"10.1161\/CIRCHEARTFAILURE.118.005544","article-title":"Proenkephalin, an opioid system surrogate, as a novel comprehensive renal marker in heart failure","volume":"12","author":"Emmens","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib141","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s00392-019-01424-y","article-title":"Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study","volume":"108","author":"Kanagala","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib142","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.hfc.2017.08.006","article-title":"Adrenomedullin as a biomarker of heart failure","volume":"14","author":"Nishikimi","year":"2018","journal-title":"Heart Fail Clin"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib143","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/0735-1097(95)00338-X","article-title":"Increased plasma levels of adrenomedullin in patients with heart failure","volume":"26","author":"Nishikimi","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib144","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/01.CIR.92.3.286","article-title":"Elevation of circulating and ventricular adrenomedullin in human congestive heart failure","volume":"92","author":"Jougasaki","year":"1995","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib145","first-page":"180","article-title":"Plasma adrenomedullin concentration in patients with heart failure","volume":"81","author":"Kato","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib146","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/eurjhf\/hfq031","article-title":"Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure","volume":"12","author":"von Haehling","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"10.1016\/j.hfc.2021.01.002_bib147","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jacc.2010.02.025","article-title":"Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial","volume":"55","author":"Maisel","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2021.01.002_bib148","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/eurjhf\/hft116","article-title":"Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure","volume":"15","author":"Xue","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib149","article-title":"Bioactive adrenomedullin in plasma is associated with biventricular filling pressures in patients with advanced heart failure","author":"Goetze","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib150","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCULATIONAHA.119.042474","article-title":"Regulatory RNAs in heart failure","volume":"141","author":"Gomes","year":"2020","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.hfc.2021.01.002_bib151","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1161\/CIRCULATIONAHA.112.093906","article-title":"Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in\u00a0vivo neovascularization and cardiac repair capacity","volume":"126","author":"Jakob","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib152","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.ijcard.2013.01.160","article-title":"Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients","volume":"168","author":"Qiang","year":"2013","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib153","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/eurjhf\/hft018","article-title":"Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure","volume":"15","author":"Dickinson","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.hfc.2021.01.002_bib154","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jchf.2015.05.012","article-title":"Association of fibroblast growth factor-23 levels and angiotensin-converting enzyme inhibition in chronic systolic heart failure","volume":"3","author":"Wohlfahrt","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2017.10.010","article-title":"Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure","volume":"253","author":"Ter Maaten","year":"2018","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib156","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/ehf2.12816","article-title":"Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction","volume":"7","author":"Roy","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib157","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.13020","article-title":"Fibroblast-growth-factor-23 in heart failure with preserved ejection fraction: relation to exercise capacity and outcomes","author":"Kanagala","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib158","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijcard.2016.11.110","article-title":"Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction","volume":"227","author":"Sinning","year":"2017","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2021.01.002_bib159","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ejhf.1058","article-title":"What have we learned about heart failure with mid-range ejection fraction one year after its introduction?","volume":"19","author":"Nauta","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib160","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.hfc.2021.01.002_bib161","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ejhf.414","article-title":"Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction","volume":"17","author":"Sanders-van Wijk","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.hfc.2021.01.002_bib162","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/eurjhf\/hfs130","article-title":"Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction","volume":"14","author":"Santhanakrishnan","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.hfc.2021.01.002_bib163","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","article-title":"Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction","volume":"72","author":"Tromp","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib164","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/CIRCULATIONAHA.112.120485","article-title":"Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management","volume":"127","author":"Januzzi","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.112.120493","article-title":"Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long","volume":"127","author":"Desai","year":"2013","journal-title":"Circulation"},{"issue":"8853","key":"10.1016\/j.hfc.2021.01.002_bib166","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0140-6736(93)93126-L","article-title":"Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction","volume":"341","author":"Motwani","year":"1993","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.hfc.2021.01.002_bib167","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000036747.68104.AC","article-title":"Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the valsartan heart failure trial (Val-HeFT)","volume":"106","author":"Latini","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hfc.2021.01.002_bib168","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.01.002_bib169","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0735-1097(01)01383-3","article-title":"Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction","volume":"38","author":"Stanek","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.hfc.2021.01.002_bib170","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib171","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/eurheartj\/ehn023","article-title":"Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients","volume":"29","author":"Pascual-Figal","year":"2008","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib172","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/eurjhf\/hfp003","article-title":"The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction","volume":"11","author":"Kub\u00e1nek","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10.1016\/j.hfc.2021.01.002_bib173","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic implications of changes in N-Terminal Pro-B-Type natriuretic peptide in patients with heart failure","volume":"68","author":"Zile","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.01.002_bib174","doi-asserted-by":"crossref","first-page":"70. e23","DOI":"10.1016\/j.amjmed.2005.08.041","article-title":"Incremental prognostic value of changes in B-type natriuretic peptide in heart failure","volume":"119","author":"Latini","year":"2006","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib175","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/ejhf.1951","article-title":"Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF","volume":"22","author":"Israr","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hfc.2021.01.002_bib176","article-title":"Personalized screening intervals for measurement of N-terminal pro-B-type natriuretic peptide improve efficiency of prognostication in patients with chronic heart failure","author":"Schuurman","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hfc.2021.01.002_bib177","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ahj.2017.10.008","article-title":"Toward personalized risk assessment in patients with chronic heart failure: detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study","volume":"196","author":"van Boven","year":"2018","journal-title":"Am Heart J"},{"issue":"18","key":"10.1016\/j.hfc.2021.01.002_bib178","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","article-title":"Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction","volume":"58","author":"Januzzi","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.hfc.2021.01.002_bib179","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2006.10.081","article-title":"Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study","volume":"49","author":"Jourdain","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9210","key":"10.1016\/j.hfc.2021.01.002_bib180","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(00)02060-2","article-title":"Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations","volume":"355","author":"Troughton","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hfc.2021.01.002_bib181","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2009.08.078","article-title":"N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study","volume":"55","author":"Berger","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.hfc.2021.01.002_bib182","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2010.07.030","volume":"56","author":"Eurlings","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.hfc.2021.01.002_bib183","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurjhf\/hfr078","article-title":"Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome","volume":"13","author":"Karlstr\u00f6m","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib184","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cardfail.2011.04.012","article-title":"The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure","volume":"17","author":"Shah","year":"2011","journal-title":"J\u00a0Card Fail"},{"issue":"8","key":"10.1016\/j.hfc.2021.01.002_bib185","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hfc.2021.01.002_bib186","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jacc.2019.06.055","article-title":"Natriuretic peptide response and outcomes in chronic heart failure with reduced ejection fraction","volume":"74","author":"Januzzi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib187","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ahj.2009.06.018","article-title":"Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials","volume":"158","author":"Felker","year":"2009","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.hfc.2021.01.002_bib188","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/archinternmed.2010.35","article-title":"B-type natriuretic peptide-guided heart failure therapy: a meta-analysis","volume":"170","author":"Porapakkham","year":"2010","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib189","doi-asserted-by":"crossref","first-page":"e58287","DOI":"10.1371\/journal.pone.0058287","article-title":"Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials","volume":"8","author":"Savarese","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.hfc.2021.01.002_bib190","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.hlc.2013.03.077","article-title":"B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials","volume":"22","author":"Li","year":"2013","journal-title":"Heart Lung Circ"},{"issue":"23","key":"10.1016\/j.hfc.2021.01.002_bib191","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/eurheartj\/ehu090","article-title":"Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis","volume":"35","author":"Troughton","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2021.01.002_bib192","first-page":"CD008966","article-title":"B-type natriuretic peptide-guided treatment for heart failure","volume":"12","author":"McLellan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.hfc.2021.01.002_bib193","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2017.11.041","article-title":"Biomarker-guided versus guideline-based treatment of patients with heart failure: results from BIOSTAT-CHF","volume":"71","author":"Ouwerkerk","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.hfc.2021.01.002_bib194","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jacc.2009.07.025","article-title":"Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure","volume":"54","author":"Miller","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.01.002_bib195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.107.694562","article-title":"Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time","volume":"116","author":"Miller","year":"2007","journal-title":"Circulation"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:42:10Z","timestamp":1761554530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713621000027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":195,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1551713621000027"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2021.01.002","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2021.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}